The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections

New England Journal of Medicine

Volumn 342, Issue 26, 2000, Pages 1930-1936

  Wong, Craig S ^a   Jelacic, Srdjan ^a   Habeeb, Rebecca L ^a   Watkins, Sandra L ^a   Tarr, Phillip I ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CHILD; DIARRHEA; ENTEROBACTER INFECTION; ESCHERICHIA COLI; FECES CULTURE; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFANT; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; DIARRHEA; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI O157; FECES; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; LOGISTIC MODELS; MALE; PROSPECTIVE STUDIES; RISK; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0034729744     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200006293422601     Document Type: Article

References (36)

1. Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI. Predictors of hemolyric uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997;100:127. abstract. (See http://www.pediatrics.org/cgi/content/full/100/1/c12.)
2. Tarr PI, Neill MA, Clausen CR, Watkins SL, Christie DL, Hickman RO. Escherichia coli O157:H7 and the hemolytic uremic syndrome: importance of early cultures in establishing the etiology. J Infect Dis 1990;162: 553-6.
3. Ostroff SM, Kobayashi JM, Lewis JH. Infections with Escherichia coli O157:H7 in Washington State: the first year of statewide disease surveillance. JAMA 1989;262:355-9.
4. Rowe P, Orrbine E, Lior H, et al. Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. J Pediatr 1998;132:777-82.
5. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983;1:619-20.
6. Ryan CA, Tauxe RV, Hosek GW, et al. Escherichia coli O157:H7 diarrhea in a nursing home: clinical, epidemiological, and pathological findings. J Infect Dis 1986;154:631-8.
7. Neill MA. Treatment of disease due to Shiga toxin-producing Escherichia coli: infectious disease management. In: Kaper JB, O'Brien AD, eds. Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. Washington, D.C.: ASM Press, 1998:357-63.
8. Pavia AT, Nichols CR, Green DP, et al. Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 1990;116:544-51.
9. Slutsker L, Ries AA, Maloney K, Wells JG, Greene KD, Griffin PM. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 1998;177:962-6.
10. Carter AO, Borczyk AA, Carlson JAK, et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987;317:1496-500.
11. Proulx F, Turgeon JP, Delagc G, Lafleur L, Chicoine L. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 1992;121:299-303.
12. Igarashi T, Inatomi J, Wake A, Takamizawa M, Katayama H, Iwata T. Failure of pre-diarrheal antibiotics to prevent hemolytic uremic syndrome in serologically proven Escherichia coli O157:H7 gastrointestinal infection. J Pediatr 1999;135:768-9.
13. March SB, Ratnam S. Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis. J Clin Microbiol 1986;23:869-72.
14. Performance standards for antimicrobial disk susceptibility tests: approved standard. 7th ed. Vol. 20. No. 1. Wayne, Pa.: National Committee for Clinical Laboratory Standards, January 2000. (NCCLS no. M2-A7.)
15. Colton T. Statistics in medicine. Boston: Little, Brown, 1974.
16. Ikeda K, Ida O, Kimoto K, Takatorige T, Nakanishi N, Tatara K. Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 1999;52:357-62.
17. Fukushima H, Hashizume T, Morita Y, et al. Clinical experiences in Sakai City Hospital during the massive outbreak of enterohemorrhagic Escherichia coli O157 infections in Sakai City, 1996. Pediatr Int 1999;41: 213-7.
18. Higami S, Nishimoto K, Kawamura T, Tsuruhara T, Isshiki G, Ookita A. Retrospective analysis of the relationship between HUS incidence and antibiotics among patients with Escherichia coli O157 enterocolitis in the Sakai outbreak. Kansenshogaku Zasshi 1998;72:266-72. (In Japanese.)
19. Kohsaka T, Tagawa M, Suzuki T, Ito H. The old and new problems of the antibiotics treatment in hemorrhagic enterocolitis and hemolytic uremic syndrome, according to Japanese epidemiological studies. Nippon Rinsho 1997;55:706-14. (In Japanese.)
20. Moriguchi N, Yagi K, Yamamoto T, Yoshioka K, Kubo S. The drug sensitivity of enterohemorrhagic Escherichia coli and antibiotics treatment for hemorrhagic enterocolitis - from an outbreak of enterocolitis in Sakai City. Jpn J Antibiot 1997;50:591-6. (In Japanese.)
21. Oshima T. Predictive factors for development of hemolytic uremic syndrome (HUS) and early intensive treatments for prevention of HUS enterohemorrhagic Escherichia coli infection. Jpn J Antibiot 1997;50:855-61. (In Japanese.)
22. Shiomi M, Togawa M, Fujita K, Murata R. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Pediatr Int 1999;41:228-32.
23. Chisaki T, Hinotani K, Shimizu T, Miyazaki K. Initial treatment at an outbreak of E. coli O-157:H7 infection: especially with respect to therapy in the emergency. Jpn J Antibiot 1997;50:821-8. (In Japanese.)
24. Yoh M, Aoki T, Akao M, Sakaue Y, Tsubura E, Honda T. Report of questionnaire about enterohaemorrhagic Escherichia coli cases caused in the area including Sakai City in 1996. Kansenshogaku Zasshi 1997;71: 1144-54. (In Japanese.)
25. Kawamura N, Yamazaki T, Tamai H. Risk factors for the development of Escherichia coli O157:H7 associated with hemolytic uremic syndrome Pediatr Int 1999;41:218-22.
26. Cimolai N, Basalyga S, Mah DG, Morrison BJ, Carter JE. A continuing assessment of risk factors for the development of Escherichia coli O157;H:7 associated hemolytic uremic syndrome. Clin Nephrol 1994;42:85-9.
27. Cimolai N, Morrison BJ, Carter JE. Risk factors for the central nervous system manifestations of gastroenteritis-associated hemolytic-uremic syndrome. Pediatrics 1992;90:616-21.
28. Cimolai N, Carter JE, Morrison BJ, Anderson JD. Risk factors for the progression of Escherichia coli O157:H7 enteritis to hemolytic-uremic syn drome. J Pediatr 1990;116:589-92. [Erratum, J Pediatr 1990;116:1008.]
29. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985;151:775-82.
30. Grif K, Dierich MP, Karch H, Allerberger F. Strain-specific difference in the amount of Shiga toxin released from enterohemorrhagic Escherichia colt O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998;17:761-6.
31. Kimmitt PT, Harwood CR, Barer MR. Induction of type 2 Shiga toxii synthesis in Escherichia coli O157 by 4-quinolones. Lancet 1999;353:1588-9.
32. Walterspiel JN, Ashkenazi S, Morrow AL, Cleary TG. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 1992;20:25-9.
33. Karch H, Strockbine NA, O'Brien AD. Growth of Escherichia coli in the presence of trimethoprim-sulfamethoxazole facilitates detection of Shiga-like toxin producing strains by colony blot assay. FEMS Microbiol Let 1986;35:141-5.
34. Goodman LJ, Trenholme GM, Kaplan RL, et al. Empiric antimicrobial therapy of domestically acquired acute diarrhea in urban adults. Arch Intern Med 1990;150:541-6.
35. Wistrom J, Jertbom M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin: a randomized placebo-controlled study Ann Intern Med 1992;117:202-8.
36. Dryden MS, Gabb RJ, Wright SK. Empirical treatment of severe acut community-acquired gastroenteritis with ciprofloxacin. Clin Infect Dis 1996;22:1019-25.